Loading...
•
Jun 30, 2023
Cullinan Oncology Q2 2023 Earnings Report
Announced second quarter 2023 financial results and provided a corporate update.
Key Takeaways
Cullinan Oncology reported a cash and investment position of $512.1 million as of June 30, 2023, which is expected to provide runway into 2026. The company also announced the initiation of a Phase 3 study of zipalertinib and presented initial clinical monotherapy data for CLN-619 at ASCO 2023.
Phase 3 first-line study of zipalertinib in EGFR exon 20 insertion mutation non-small-cell lung cancer (NSCLC) patients (REZILIENT-3) is open for enrollment.
Initial monotherapy clinical data for CLN-619 was presented at ASCO 2023 Annual Meeting; monotherapy expansion cohorts in endometrial and cervical cancers were initiated.
The first patient was dosed in Phase 1 study of CLN-978 in relapsed/refractory (R/R) B Cell non-Hodgkin lymphoma (B-NHL).
Cash and investment position of $512.1 million as of June 30, 2023, which is expected to provide runway into 2026.
Cullinan Oncology
Cullinan Oncology
Forward Guidance
Cullinan Oncology expects its cash resources to provide runway into 2026 based on its current operating plan.